$11.80
-0.88-6.94%
最終更新: Oct 16, 7:53 PM
$11.80
-0.88-6.94%
Benzinga
Benzinga
Benzinga
土曜日, 10 17
Benzinga
© 2026 Benzinga | All Rights Reserved
AbCellera Biologics (ABCL) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.17 | $-0.20 | $-0.18 | $-0.17 |
| Actual | $-0.18 | $-0.14 | $-0.03 | $-0.19 |
| Surprise | -5.88% | +30.0% | +83.3% | -11.8% |
| Revenue | ||||
| Estimate | $7.8M | $5.7M | $6.7M | $6.4M |
| Actual | $4.0M | $8.3M | $44.9M | $9.0M |
| Surprise | -48.1% | +46.9% | +568.2% | +38.9% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.18 | $-0.18 | $-0.20 | $-0.21 |
| Revenue | ||||
| Consensus | $6.1M | $6.7M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.18 | $-0.17 | -5.88 % |
| Q1 | May 11, 2026 | $-0.14 | $-0.20 | 30.0 % |
| Q4 | Feb 24, 2026 | $-0.03 | $-0.18 | 83.3 % |
| Q3 | Nov 6, 2025 | $-0.19 | $-0.17 | -11.8 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $4.05M | $7.80M | -48.1 % |
| Q1 | May 11, 2026 | $8.32M | $5.66M | 46.9 % |
| Q4 | Feb 24, 2026 | $44.90M | $6.72M | 568.2 % |
| Q3 | Nov 6, 2025 | $8.96M | $6.45M | 38.9 % |